Longeveron Inc. (LGVN)

NASDAQ: LGVN · IEX Real-Time Price · USD
-0.07 (-3.59%)
At close: Nov 27, 2023, 4:00 PM
+0.10 (5.32%)
After-hours: Nov 27, 2023, 4:53 PM EST

Company Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.

The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty.

The company was incorporated in 2014 and is headquartered in Miami, Florida.

Longeveron Inc.
Longeveron logo
Country United States
Founded 2014
IPO Date Feb 12, 2021
Industry Biotechnology
Sector Healthcare
Employees 19
CEO Mohamed Wa'el Ahmed Hashad

Contact Details

1951 Nw 7th Avenue, Suite 520
Miami, Florida 33136
United States
Phone 305-302-7158
Website longeveron.com

Stock Details

Ticker Symbol LGVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001721484
CUSIP Number 54303L104
ISIN Number US54303L1044
Employer ID 47-2174146
SIC Code 2834

Key Executives

Name Position
Dr. Joshua Michael Hare FACC, M.D. Co-Founder, Chief Science Officer and Chairman
James Clavijo CPA Chief Financial Officer and Treasurer
Paul T. Lehr J.D. International Executive Director, General Counsel and Secretary
Dr. Kwan-Hong Min M.D., Ph.D. Chief Medical Officer and Interim Chief Executive Officer
Dr. Dan Gincel Ph.D. Senior Vice President of Strategic Collaborations and Scientific Affairs

Latest SEC Filings

Date Type Title
Nov 21, 2023 EFFECT Notice of Effectiveness
Nov 15, 2023 S-1 General form for registration of securities under the Securities Act of 1933
Nov 14, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 14, 2023 DEF 14A Other definitive proxy statements
Nov 9, 2023 10-Q Quarterly Report
Nov 2, 2023 PRE 14A Other preliminary proxy statements
Oct 24, 2023 D Notice of Exempt Offering of Securities
Oct 13, 2023 8-K Current Report
Oct 13, 2023 424B5 Filing
Oct 5, 2023 8-K Current Report